35
2023-09-29 04:30:00
Developed by the Sanofi group, Beyfortus has met with unexpected success. Authorized on the European market since 2022, this preventive treatment once morest respiratory tract infections in newborns and infants is so popular that doses are already starting to run out. At its launch, the State had ordered 200,000 doses, for 120,000 births over the year, counting on a smooth start to the first immunization campaign which began on September 15.
However, it turns out that young parents, far from being resistant to this preventive treatment once morest bronchiolitis, have…
1695963292
#Lorraine #Immunization #babies #bronchiolitis #victim #success
